

## TORRENT PHARMACEUTICALS LIMITED


Registered Office: Torrent House, Off Ashram Road, Ahmedabad - 380 009, Ph.: + 91 79 26599000 Fax: + 91 79 26582100

CIN: L24230GJ1972PLC002126; Website:www.torrentpharma.com; Email: investorservices@torrentpharma.com

(Rs. in crores except per share data)

### Statement of Consolidated Financial Results for the Quarter and Year Ended 31-Mar-2019

Particulars	Quarter ended		Year ended		
	31-Mar-2019 (Audited)	31-Dec-2018 (Unaudited)	31-Mar-2018 (Audited)	31-Mar-2019 (Audited)	31-Mar-2018 (Audited)
	(Refer Note 7)		(Refer Note 7)		
<b>Revenue</b>					
Net sales	1822	1948	1666	7462	5825
Other operating income	34	103	42	211	125
<b>Revenue from operations (net)</b>	<b>1856</b>	<b>2051</b>	<b>1708</b>	<b>7673</b>	<b>5950</b>
Other income	17	3	42	57	299
<b>Total revenue</b>	<b>1873</b>	<b>2054</b>	<b>1750</b>	<b>7730</b>	<b>6249</b>
<b>Expenses</b>					
Cost of materials consumed	360	335	348	1290	1039
Purchases of stock-in-trade	144	216	290	846	997
Changes in inventories of finished goods, work-in-progress and stock-in-trade	29	29	(175)	83	(362)
Employee benefits expense	347	368	317	1404	1135
Finance costs	123	133	121	504	308
Depreciation amortisation and impairment expense	160	156	151	618	409
Other expenses	503	542	564	2066	1792
<b>Total expenses</b>	<b>1666</b>	<b>1779</b>	<b>1616</b>	<b>6811</b>	<b>5318</b>
<b>Profit / (Loss) before exceptional items and tax</b>	<b>207</b>	<b>275</b>	<b>134</b>	<b>919</b>	<b>931</b>
Exceptional items (Refer note 11)	357	-	-	357	-
<b>Profit / (Loss) before tax</b>	<b>(150)</b>	<b>275</b>	<b>134</b>	<b>562</b>	<b>931</b>
Tax expense					
Current Tax	63	92	54	280	199
Deferred Tax	(61)	(64)	(143)	(155)	(8)
Short / (excess) provision of earlier periods	-	1	(5)	1	62
<b>Total tax expense</b>	<b>2</b>	<b>29</b>	<b>(94)</b>	<b>126</b>	<b>253</b>
<b>Net Profit / (Loss) for the period</b>	<b>(152)</b>	<b>246</b>	<b>228</b>	<b>436</b>	<b>678</b>
Attributable to :					
- Owners of the company	(152)	246	228	436	678
- Non controlling Interest *	0	0	0	0	0
<b>Other Comprehensive Income</b>					
Items that will not be reclassified to profit or loss*	0	(3)	8	(9)	(0)
Income tax relating to items that will not be reclassified to profit or loss*	0	1	(1)	3	2
Items that will be reclassified to profit or loss	74	178	(68)	54	(202)
Income tax relating to items that will be reclassified to profit or loss	(21)	(51)	17	(15)	59
<b>Total other comprehensive income</b>	<b>53</b>	<b>125</b>	<b>(44)</b>	<b>33</b>	<b>(141)</b>
<b>Total Comprehensive Income</b>	<b>(99)</b>	<b>371</b>	<b>184</b>	<b>469</b>	<b>537</b>
Attributable to :					
- Owners of the company	(99)	371	184	469	537
- Non controlling Interest *	0	0	0	0	0
Paid-up equity share capital (Face value of Rs. 5 each)	84.62	84.62	84.62	84.62	84.62
Paid up Debt Capital				1957	2899
Other Equity excluding Revaluation Reserves				4639	4537
Networth				4724	4622
Debt Redemption Reserve				489	725
<b>Earnings per share (of Rs. 5/- each) before exceptional items net of taxes (not annualised for the quarter):</b>					
Basic & Diluted	7.72	14.50	13.55	42.45	40.07
<b>(Loss) / Earnings per share (of Rs. 5/- each) after exceptional items net of taxes (not annualised for the quarter):</b>					
Basic & Diluted	(8.95)	14.50	13.55	25.78	40.07
Debt Equity Ratio				1.08	1.05
Debt Service Coverage Ratio				1.19	2.32
Interest Service Coverage Ratio				2.83	4.05



\* Less than Rs. 1 crore

Ratios have been computed as follows :-

a) Debt to Equity: Debt / Net Worth

Debt: Long term borrowings (Current & Non Current Portion)

Net worth: Share Capital + Reserves & Surplus

b) Debt Service Coverage Ratio: EBIT / (Interest on term & working capital debt + Principal repayments of Long term debt)

(EBIT : Profit before Taxes +/- Exceptional Items + Interest Expense)


c) Interest Service Coverage Ratio: EBIT / Interest Expense

**Notes:**

- The above results were reviewed by the Audit and Risk Management Committee and approved by the Board of Directors of the Parent Company, in their respective meetings held on 20-May-2019. The auditor have carried out an audit of the above said results. There is no qualification in the auditor's report on this statement of financial results.
- The consolidated financial results include the financial results of sixteen wholly owned subsidiaries and one partnership firm with that of the Company. Partnership firm has been dissolved with effect from 31-Mar-2019.
- The Group operates in a single segment i.e Generic Formulation Business.
- The Parent Company has acquired branded business of Unichem Laboratories Limited for India and Nepal on a going concern basis by way of slump sale on 14-Dec-2017. The financial results for the year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired business from the date of acquisition.
- Torrent Pharma Inc., wholly owned subsidiary of Parent Company, has acquired 100% equity shares of Bio-Pharm Inc., on 18-Jan-2018. The financial results for the quarter and year ended 31-Mar-2018 includes revenue and expenses (including amortisation and interest) of the acquired entity from the date of acquisition. Bio-Pharm Inc. has been merged with Torrent Pharma Inc. with effect from 01-Jan-2019.
- Consolidated Statement of Assets and Liabilities :

(Rs. in Crores)

Particulars	Audited	Audited
	As at 31-Mar-2019	As at 31-Mar-2018
<b>ASSETS</b>		
<b>Non-current assets</b>		
Property, plant and equipment	2801	2417
Capital work-in-progress	479	423
Goodwill	335	399
Other intangible assets	4612	5039
Intangible assets under development	138	224
Financial assets		
Investments*	2	0
Loans	3	3
Other financial assets	146	21
	151	24
Non-current tax assets (net)	120	90
Deferred tax assets (net)	370	276
Other non-current assets	77	89
<b>Sub-total - Non-current assets</b>	<b>9083</b>	<b>8981</b>
<b>Current assets</b>		
Inventories	1935	1966
Financial assets		
Investments	351	492
Trade receivables	1436	1254
Cash and cash equivalents	589	241
Bank balances other than cash and cash equivalents	227	626
Loans	4	3
Other financial assets	65	159
	2672	2775
Other current assets	431	521
Non-current assets held for sale*	0	0
<b>Sub-total - Current assets</b>	<b>5038</b>	<b>5262</b>
<b>TOTAL - ASSETS</b>	<b>14121</b>	<b>14243</b>



(Rs. in Crores)

Particulars	Audited	Audited
	As at 31-Mar-2019	As at 31-Mar-2018
<b>EQUITY AND LIABILITIES</b>		
<b>Equity</b>		
Share capital	85	85
Other Equity	4639	4537
<b>Equity attributable to owners of the company</b>	<b>4724</b>	<b>4622</b>
<b>Non-controlling interests</b>	<b>-</b>	<b>1</b>
<b>Sub-total - Equity</b>	<b>4724</b>	<b>4623</b>
<b>Non-current liabilities</b>		
Financial Liabilities		
Borrowings	3913	4111
Other financial liabilities	15	18
	3928	4129
Provisions	289	287
Deferred tax liabilities (net)*	7	0
Other non-current liabilities	7	2
<b>Sub-total - Non-current liabilities</b>	<b>4231</b>	<b>4418</b>
<b>Current liabilities</b>		
Financial Liabilities		
Borrowings	934	1626
Trade payables		
Due to micro and small enterprises	7	7
Due to others	2091	2041
Other financial liabilities	1523	1052
	4555	4726
Provisions	414	327
Current tax liabilities (net)	79	49
Other current liabilities	118	100
<b>Sub-total - Current liabilities</b>	<b>5166</b>	<b>5202</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>14121</b>	<b>14243</b>

\* Less than Rs. 1 crore

- 7 The figures for the quarter ended 31-Mar-2019 and 31-Mar-2018 are the balancing figures between audited figures in respect of the full financial year and for the period upto the end of the third quarter of financial year, which were subject to limited review.
- 8 Deferred tax expense during the year ended 31-Mar-2019 includes MAT credit of Rs. 73 crores pertaining to earlier period.
- 9 (a) The listed Non Convertible Debentures of the Parent Company aggregating Rs. 1957 crores as on 31-Mar-2019 (previous year ended Rs. 1399 crores) are secured by way of first pari passu charge created through mortgage on certain specified immovable & movable assets and hypothecation of identified trademarks of the Parent Company and the asset cover thereof exceeds hundred percent of the principal amount of the said debentures.
- (b) The listed Non Convertible Debentures of the company aggregating Rs. Nil as on 31-Mar-2019 (previous year ended Rs. 1000 crores) to be secured by way of first pari passu charge on certain specified immovable & movable assets and identified trademarks of the Company.
- 10 Effective 1 April 2018, the Company has adopted Ind AS 115 "Revenue from Contracts with Customers". The adoption of the standard did not have material impact on the financial results of the Group.
- 11 Exceptional items for the quarter and year ended 31-Mar-2019 includes :
- (i) Rs. 217 crores pertaining to impairment provision of certain intangible assets, intangible assets under development and goodwill recognised with respect to the acquisition of Bio-Pharm, Inc. (merged with Torrent Pharma Inc. with effect from 01-Jan-2019).
- (ii) Rs. 140 crores in relation to product recalls made during the current year. These expenses include write down of inventory, certain contractual obligations and recall expenses.
- 12 The Board of Directors in their meeting held on 20-May-2019, declared a final equity dividend of Rs. 4.00 per equity share.
- 13 The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.



For TORRENT PHARMACEUTICALS LIMITED

SAMIR MEHTA  
Executive ChairmanPlace : Ahmedabad, Gujarat  
Date : 20-May-2019